Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity.

Front Oncol · 2025 · PMC12308200 · PMID 40740880

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not significantly significantno p-value reported

This may suggest a modest benefit to administering DOX over multiple days, although the differences were not significantly significant.

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.